An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread



Status:Recruiting
Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/2/2019
Start Date:June 16, 2016
End Date:October 15, 2021
Contact:Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:
Email:Clinical.Trials@bms.com

Use our guide to learn which trials are right for you!

A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination With Nivolumab and/or Ipilimumab in Advanced Solid Tumors

The purpose of the study is to determine the safety and tumor-shrinking ability of
experimental medication BMS-986178, when given by itself or in combination with Nivolumab
and/or Ipilimumab, in patients with solid cancers that are advanced or have spread.


For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Patients must have at least 1 standard treatment regimen in the advanced, recurrent or
metastatic setting

- ECOG (Eastern Cooperative Oncology Group) 0-1

- Men and women 18 years old or older

- At least one measurable lesion at baseline by CT (computed tomography) or MRI
(magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid
Tumors) v1.1

- All subjects must have a fresh tumor biopsy

Exclusion Criteria:

- Known central nervous system metastases or central nervous system as the only source
of disease

- Concomitant malignancies

- Active known or suspected autoimmune disease

- Uncontrolled or significant cardiovascular disease

- Major surgery less than 4 weeks before the start of the study

- Patients with known allergies to egg products, neomycin, or tetanus toxoid

- Prior adverse reaction to tetanus toxoid-containing vaccines

Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
9
sites
New York, New York 10032
Phone: 646-317-3141
?
mi
from
New York, NY
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Phone: 716-845-4101
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Phone: 503-215-5696
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Aurora, Colorado 80045
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Edmonton, Alberta
Phone: 7809898157
?
mi
from
Edmonton,
Click here to add this to my saved trials
92 2nd St
Hackensack, New Jersey 07601
(201) 996-5900
Phone: 551-996-5900
John Theurer Cancer Center at the Hackensack University Medical Center The mission of the John...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19102
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
3800 Reservoir Rd NW
Washington, District of Columbia 20007
(202) 687-7695
Phone: 202-444-2144
Georgetown University Medical Center Georgetown University Medical Center is committed to excellence in research, education...
?
mi
from
Washington,
Click here to add this to my saved trials